Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present invention relates to the medical field, and in particular to the use of adefovir dipivoxil and a structural analog thereof for treating pseudorabies virus. In particular, the invention relates to the use of a compound as shown in formula (I), a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a solvate of the pharmaceutically acceptable salt thereof for inhibiting the pseudorabies virus, treating pseudorabies virus infections or treating diseases related to pseudorabies virus infections.

##STR00001##

A method of reducing TET2 mutant allele burden in a subject, comprising: administering to a subject identified as having a TET2 mutation a 50 to 540 μg dose of a pegylated interferon-α at a regular interval of 2 to 8 weeks for a treatment period, the pegylated interferon-α being a conjugate of formula I:

##STR00001##

in which each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, independently, is H, C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkynyl, aryl, heteraryl, C.sub.3-8 cycloalkyl, or C.sub.3-8 heterocycloalkyl; each of A.sub.1 and A.sub.2, independently, is a polymer moiety; each of G.sub.1, G.sub.2, and G.sub.3, independently, is a bond or a linking functional group; P is an interferon-α moiety; m is 0 or an integer of 1-10; and n is an integer of 1-10,
wherein the subject has a reduction in TET2 mutant allele burden at a second time point in the treatment period as compared to a first time point before or earlier in the treatment period.

Disclosed are methods and compositions for at least preventing, treating, inhibiting, or attenuating an Ebola virus infection of a subject. The methods comprise administering an effective amount of a composition as described herein to the subject thereby at least preventing, treating, inhibiting, or attenuating the Ebola virus infection of the subject. The compositions comprise a therapeutic double-stranded RNA (tdsRNA) and additional optional components such as an Ebola antigen.

The invention described herein relates to methods for treating a patient having a plurality of HLA-negative cancer cells or cancer cells with reduced HLA expression with IFN-alpha in an amount sufficient to expand and/or activate immune cells such that the activated and/or expanded immune cells kill one or more of HLA-negative cancer cells or the cancer cells with reduced HLA expression.

Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

A compound represented by Formula 1 according to the present disclosure, when used in combination with an anticancer drug, may significantly improve the anticancer effect of the anticancer drug, and may induce the same anticancer effect even when the anticancer drug is used in a significantly smaller amount than the conventionally used amount, thereby reducing the side effects caused by administration of the anticancer drug. Furthermore, the compound represented by Formula 1 makes it possible to effectively prevent, alleviate or treat either anticancer-resistant cancer or cancer which recurs or metastasizes after anticancer drug treatment.

Disclosed in a method of treating a myeloid neoplasm, acute leukemia, or infectious disease in a subject, the method including administering to a subject in need thereof a pegylated interferon-α at a regular interval of every 2 to 8 weeks at a first dose of 250 to 500 μg.

A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of GVYDGEEHSV (SEQ ID NO: 303), in which the peptide is in a complex with an MHC molecule.